53 results about "Tau pathology" patented technology

Intranasal administration of insulin for a predetermined period prior to anesthesia significantly prevented anesthesia-induced tau hyperphosphorylation and cognitive impairment and enhanced brain insulin signaling in mice. Intranasal insulin thus provides a treatment for prevention of anesthesia-induced tau pathology and increased risk for tauopathies in surgical patients and may be administered to a subject prior to anesthesia, such as by administering several doses of intranasal insulin for several consecutive days prior to any anesthesia.

A method of treating tau pathologies, such as Alzheimer's disease, involving the administration of antibodies specific to the amino terminal region of human tau (amino acid residues 6-18 or 184-195) to provide passive immunization. The administration of such antibodies can reduce total tau levels, decrease tau hyperphosphorylation, and improve reference memory. Passive immunization with antibodies targeting the N-terminal projection domain of tau reduces both total and hyperphosphorylated tau was found effective in aged 3×Tg-AD mice, a generally accepted mouse model of Alzheimer's disease and frontotemporal dementia in humans.

The invention relates to the field of biotechnology and particularly relates to a method for establishing an Alzheimer disease pathologic model based on the transgenic technology. In the invention, the Alzheimer disease pathologic model is established by generally over-expressing an HO-1 (heme oxygenase-1) gene in a mouse by using the transgenic technology. The transgenic mouse automatically forms the Alzheimer disease tau pathology, which is an ideal animal model for researching the generation mechanism of neurofibrillary tangles as a typical pathologic symbol of Alzheimer disease.

The invention discloses a method for constructing an Alzheimer disease mouse model. A genotype FVB-Fgf14Tg (tetO-MAPT* P301L) 4510 Kha/JlwsJ female mouse is adopted, a truncated tau protein or a vector expressing the truncated tau protein is injected into the brain of the mouse at the age of 4 months and then the mouse is fed for 2-4 months, and the amino acid sequence of the truncated tau proteinis as shown in SEQ ID NO: I. The Alzheimer disease mouse model is successfully constructed, tau pathology only appears in the hippocampus region of the constructed mouse model, and does not appear inother brain regions, the construction period is shortened to 6 months, and more than 50% of modeling time is saved.

The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

The invention discloses a method for accelerating protein-like propagation of tau pathology in the brain of a C57BL6 mouse. The method comprises the following steps: constructing an RNAi adeno-associated virus vector; co-transfecting an AAV-293 cell with virus-packaged helper plasmids and the RNAi adeno-associated virus vector (a high-quality recombinant vector) of a target gene to obtain an RNAieffective vector adeno-associated virus; injecting the virus into the body of the C57BL/6 mouse; and constructing a target gene overexpression vector, co-transfecting a 293T cell with the target geneoverexpression vector and the RNAi adeno-associated virus vector of the target gene, observing cell fluorescence to ensure that the transfection efficiency is greater than or equal to 70 percent, collecting cell extraction proteins, and detecting the knock-down condition of the target gene. According to the method, a rAAV9 gene can be used as an effective tool vector for delivering genes in braintissues, so that the protein-like propagation rate of the tau pathology in the brain of the mouse is increased.

The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a TGII (activator of the protein kinase cdk 5) polypeptide. The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid β peptides and hyperphosphorylated tau, respectively. While animal models for plaque formation exist, there is no animal model that recapitulates the formation of NFTs. This invention provides transgenic mice that overexpress human TGII, an activator of cdk5, resulting in tau that is hyperphosphorylated at AD-relevant epitopes. Deposition of tau is detected in the amygdala, thalamus and cortex. Increased phosphorylated neurofilament, silver-positive neurons and neuronal death are also observed in these regions. We conclude that the overexpression of TGII, an activator of cdk5, is sufficient to produce hyperphosphorylation of tau and neuronal death. The TGII transgenic mouse represents the first model for tau pathology in AD.

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.

The invention discloses a method for inhibiting tau pathological prion transmission through mediation of adeno-associated viruses. The method comprises the following steps: constructing a recombinant adeno-associated virus; injecting the constructed adeno-associated virus into the right ventricle of a mouse in a ventricle injection manner; separating pathological tau, namely AD O-tau, extracted from the brain of an AD patient; and injecting the separated AD O-tau into the hippocampus of the mouse. Results show that rAAV9 can be used as an effective tool vector for delivering genes in brain tissues, over-expression of a PP2A gene is mediated through a virus vector, and dephosphorylation of tau is increased, so a molecular mechanism of tau pathogenesis is studied, the relationship between tau pathology aggregation and prion transmission and tau phosphorylation level and PP2A is defined, the feasibility of rAAV vector mediated gene therapy is prompted, the screening of drugs for inhibiting or reversing the generation, development and transmission of tau pathology can be facilitated, and a new strategy is provided for the treatment of such diseases.

The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the ^{p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody -based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.